Personalized Voice Activated Wellness Assistants for Patients With Heart Failure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03707275 |
Recruitment Status :
Completed
First Posted : October 16, 2018
Last Update Posted : June 19, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heart Failure Congestive Heart Failure | Device: Alexa+ Other: Standard of Care Arm | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Personalized Voice Activated Wellness Assistants for Patients With Heart Failure |
Actual Study Start Date : | December 10, 2018 |
Actual Primary Completion Date : | October 31, 2019 |
Actual Study Completion Date : | October 31, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Alexa+ Arm |
Device: Alexa+
Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies. |
Standard of Care Arm |
Other: Standard of Care Arm
This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR. |
- Change in comfort level using Alexa+ technology as measured by the pre and post-test technology comfort survey [ Time Frame: 3 months ]
- Change in number of hospitalizations as measured by hospitalization data extracted from the EHR [ Time Frame: 3 months ]
- Change in medication adherence as measured by number of prescriptions filled extracted from the EHR [ Time Frame: 3 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Heart failure patients seen at the MedStar heart failure clinic and the MedStar Washington Hospital Center inpatient heart failure service
- At least 18 years of age
- Have access to in-home Wi-Fi
Exclusion Criteria:
- Participation in another interventional clinical trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03707275
United States, District of Columbia | |
MedStar Washington Hospital Center | |
Washington, District of Columbia, United States, 20010 |
Principal Investigator: | Nawar M Shara, M.S., PhD | Medstar Health Research Institute |
Responsible Party: | Nawar Shara, Director, Department of Biostatistics and Biomedical Informatics, Medstar Health Research Institute |
ClinicalTrials.gov Identifier: | NCT03707275 |
Other Study ID Numbers: |
Alexa+ Study UL1TR001409 ( U.S. NIH Grant/Contract ) |
First Posted: | October 16, 2018 Key Record Dates |
Last Update Posted: | June 19, 2020 |
Last Verified: | June 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | The findings from this study will be disseminated through formal presentations and informal frequent communications with participants in this study. Results will be presented at a national meeting and a report to document the results of the pre-and-post questionnaires as well as the data generated from Alexa will also be shared with researchers as appropriate. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Clinical trial Patient-centered outcomes Treatment of heart failure Technology in heart failure |
Heart Failure Heart Diseases Cardiovascular Diseases |